

GERRESHEIMER



**Gerresheimer Capital Markets Day:
Update on financial performance**

October 23+24, 2008

Hans-Jürgen Wiecha, CFO

Disclaimer


- This presentation may contain certain forward-looking statements, including assumptions, opinions and views of the Company or cited from third party sources. Various known and unknown risks, uncertainties and other factors could cause the actual results, financial position, development or performance of the Company to differ materially from the estimations expressed or implied herein.
- The Company does not guarantee that the assumptions underlying such forward-looking statements are free from errors nor does the Company accept any responsibility for the future accuracy of the opinions expressed in this Presentation or the actual occurrence of the forecast development.
- No representation or warranty (express or implied) is made as to, and no reliance should be placed on, any information, including projections, estimates, targets and opinions, contained herein, and no liability whatsoever is accepted as to any errors, omissions or misstatements contained herein, and, accordingly, none of the Company or any of its parent or subsidiary undertakings or any of such person's officers, directors or employees accepts any liability whatsoever arising directly or indirectly from the use of this document.

Excellent group sales and earnings development YTD

Net sales and adjusted EBITDA EUR m

Net sales growth at constant exchange rate: 15.8%

Adj. EBITDA margin:
Q1-Q3 2008: 18.8%
Q1-Q3 2007: 17.8%



- Net sales growth driven by high demand for pharma and cosmetic products
- Margin expansion across all divisions
- All four divisions contributed positively to sales and earnings growth


¹ Earnings before financial result, income taxes, amortization of fair value adjustments, extraordinary depreciation, depreciation and amortization, restructuring expenses and one-off income and expenses

Tubular Glass: Favorable sales trends in RTF syringes and vials drive growth

Net sales and adjusted EBITDA EUR m

Net sales growth at constant exchange rate: 16.5%

Adj. EBITDA margin:
Q1-Q3 2008: 24.5%
Q1-Q3 2007: 24.0%



- Sales of RTF syringes up 48.9% compared with Q1-Q3 2007
- Continued strong sales of vials in America and China


¹ Earnings before financial result, income taxes, amortization of fair value adjustments, extraordinary depreciation, depreciation and amortization, restructuring expenses and one-off income and expenses

Plastic Systems: Margin increase reflects operational progress

Net sales and adjusted EBITDA EUR m

Net sales growth at constant exchange rate: 17.8%

Adj. EBITDA margin:
Q1-Q3 2008: 18.4%
Q1-Q3 2007: 17.5%



- Strong growth driven by favorable development in Inhalation and Diagnostics
- Further growth through recent acquisitions
- Focus on core business; TPS selling process on track
- Pen production about to start


¹ Earnings before financial result, income taxes, amortization of fair value adjustments, extraordinary depreciation, depreciation and amortization, restructuring expenses and one-off income and expenses

Moulded Glass: Outperformance of market growth

Net sales and adjusted EBITDA EUR m

Net sales growth at constant exchange rate: 8.4%

Adj. EBITDA margin:
Q1-Q3 2008: 21.1%
Q1-Q3 2007: 19.3%



- Pharma bottles in US and Europe and cosmetic products in European and emerging markets drove sales
- Additional contribution generated by high capacity utilization


¹ Earnings before financial result, income taxes, amortization of fair value adjustments, extraordinary depreciation, depreciation and amortization, restructuring expenses and one-off income and expenses

Life Science Research: Margin uplift of 230 basis points

Net sales and adjusted EBITDA EUR m

Net sales growth at constant exchange rate: +61.6%

Adj. EBITDA margin:
Q1-Q3 2008: 11.9%
Q1-Q3 2007: 9.6%



- High growth in sales and adjusted EBITDA triggered by Kimble Chase JV
- Ongoing portfolio optimization
- Joint product campaigns well-received by customers

¹ Earnings before financial result, income taxes, amortization of fair value adjustments, extraordinary depreciation, depreciation and amortization, restructuring expenses and one-off income and expenses


Solid capital structure

EUR m	Q1-Q3 as of Aug 31, 2008	Q1-Q3 as of Aug 31, 2007	▲	FY 2007 as of Nov 30, 2007
Equity Equity ratio in %	480.2 33.6	491.5 34.2	-2.3%	499.9 34.8
Net working capital¹ in % of LTM net sales	205.9 19.7	187.0 21.6	+10.1%	179.8 18.8
Net financial debt²	437.8	414.3	+5.7%	390.6
Adjusted EBITDA leverage	2.1	2.4	-	2.2
	Dec 1, 2007 – Aug 31, 2008	Dec 1, 2006 – Aug 31, 2007	▲	Dec 1, 2006 – Nov 30, 2007
Capital expenditure	54.4	62.3	-12.7%	98.9

¹ Inventories, trade receivables and prepayments on account of orders less trade payables and payments received on account of orders

² Total amount of debt less cash and cash equivalents

Constant decrease of leverage




Secured long-term financing structure; liquidity reserves through EUR 175m committed revolver

Debt/cash positions in EUR m ¹	Interest rate	Due by
Net financial debt	437.8	
Bond	126.0	7.9%; Fixed coupon
Long-term bank debt	232.0	5.7%; Hedged 100% until Sep 2010
Revolving bank debt	36.2	55bps over Euribor/Libor; Headroom: EUR 139m
Local borrowings	55.9	5.5% (average)
Leasing	24.8	5.5% (average)
Cash	37.1	

¹ As of August 31, 2008

Further investments in profitable growth projects

Capex by segment in EUR m



Major investments:

- 3rd production line for RTF syringes
- New facility for pen production in the Czech Republic
- Expansion of inhaler production facilities at Gerresheimer Wilden
- Greenfield Tubular Glass plant in China